Immunic, inc. reports second quarter 2025 financial results and provides corporate update

– vidofludimus calcium substantially reduced 24-week confirmed disability worsening in phase 2 calliper trial in overall progressive multiple sclerosis study population and across subtypes, reinforcing the drug's neuroprotective potential and ability to slow disease progression – – completed enrollment for both phase 3 ensure trials of vidofludimus calcium in relapsing multiple sclerosis; top-line data expected by end of 2026 – – new long-term open-label extension data from phase 2 emphasis trial in relapsing-remitting multiple sclerosis showed high rates of patients remaining free of 12-week and 24-week confirmed disability worsening  – – strengthened balance sheet with two financings totaling $70.1 million in gross proceeds – new york , aug. 7, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter and six months ended june 30, 2025, and provided a corporate update. "during the second quarter and more recently, we have made substantial clinical progress in advancing our potentially transformative lead asset, vidofludimus calcium (imu-838), an orally available nuclear receptor-related 1 (nurr1) activator," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking